Dyskinesia, Drug-Induced

"Dyskinesia, Drug-Induced" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)

Descriptor ID	D004409
MeSH Number(s)	C10.228.662.262.500 C10.597.350.275 C10.720.312 C23.888.592.350.275 C25.100.750 C25.723.705.200
Concept/Terms	Dyskinesia, Drug-Induced Dyskinesia, Drug-Induced Drug-Induced Dyskinesia Drug-Induced Dyskinesias Dyskinesia, Drug Induced Dyskinesias, Drug-Induced Dyskinesia, Medication-Induced Dyskinesia, Medication-Induced Dyskinesia, Medication Induced Dyskinesias, Medication-Induced Medication-Induced Dyskinesias Medication-Induced Dyskinesia Medication Induced Dyskinesia

Below are MeSH descriptors whose meaning is more general than "Dyskinesia, Drug-Induced".

Diseases [C]
Nervous System Diseases [C10]
Central Nervous System Diseases [C10.228]
Movement Disorders [C10.228.662]
Dyskinesias [C10.228.662.262]
Dyskinesia, Drug-Induced [C10.228.662.262.500]
Neurologic Manifestations [C10.597]
Dyskinesias [C10.597.350]
Dyskinesia, Drug-Induced [C10.597.350.275]
Neurotoxicity Syndromes [C10.720]
Dyskinesia, Drug-Induced [C10.720.312]
Pathological Conditions, Signs and Symptoms [C23]
Signs and Symptoms [C23.888]
Neurologic Manifestations [C23.888.592]
Dyskinesias [C23.888.592.350]
Dyskinesia, Drug-Induced [C23.888.592.350.275]
Chemically-Induced Disorders [C25]
Drug-Related Side Effects and Adverse Reactions [C25.100]
Dyskinesia, Drug-Induced [C25.100.750]
Poisoning [C25.723]
Neurotoxicity Syndromes [C25.723.705]
Dyskinesia, Drug-Induced [C25.723.705.200]

Below are MeSH descriptors whose meaning is more specific than "Dyskinesia, Drug-Induced".

Dyskinesia, Drug-Induced
Tardive Dyskinesia

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Dyskinesia, Drug-Induced" by people in this website by year, and whether "Dyskinesia, Drug-Induced" was a major or minor topic of these publications.

Bar chart showing 6 publications over 6 distinct years, with a maximum of 1 publications in 1996 and 1999 and 2004 and 2005 and 2019 and 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1999	1	0	1
2004	0	1	1
2005	1	0	1
2019	1	0	1
2021	0	1	1

Below are the most recent publications written about "Dyskinesia, Drug-Induced" by people in Profiles.

Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, de Bie RMA, Roze E, Miyasaki JM, Hauser RA, Espay AJ, Martello JP, Gurwell JA, Billinghurst L, Sullivan K, Fitts MS, Cothros N, Hall DA, Rafferty M, Hagerbrant L, Hastings T, O'Brien MD, Silsbee H, Gronseth G, Lang AE. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology. 2021 11 16; 97(20):942-957.

View in: PubMed
Hauser RA, Kremens DE, Elmer LW, Kreitzman DL, Walsh RR, Johnson R, Howard R, Nguyen JT, Patni R. Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials. J Parkinsons Dis. 2019; 9(3):591-600.

View in: PubMed
Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, Mach U, Stark H, Leriche L, H?kansson K, Bioulac BH, Gross CE, Sokoloff P, Fisone G, Gurevich EV, Bloch B, Bezard E. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat Disord. 2005 Jun; 11 Suppl 1:S25-9.

View in: PubMed
Brasic JR, Barnett JY, Kowalik S, Tsaltas MO, Ahmad R. Neurobehavioral assessment of children and adolescents attending a developmental disabilities clinic. Psychol Rep. 2004 Dec; 95(3 Pt 2):1079-86.

View in: PubMed
Baca-Garcia E, Stanilla JK, B?chel C, Gattaz WF, de Leon J. Diurnal variability of orofacial dyskinetic movements. Pharmacopsychiatry. 1999 Mar; 32(2):73-5.

View in: PubMed
Stanilla JK, B?chel C, Alarcon J, de Leon J, Simpson GM. Diurnal and weekly variation of tardive dyskinesia measured by digital image processing. Psychopharmacology (Berl). 1996 Apr; 124(4):373-6.

View in: PubMed
Lidsky TI. Reevaluation of the mesolimbic hypothesis of antipsychotic drug action. Schizophr Bull. 1995; 21(1):67-74.

View in: PubMed
Lazarus A, Dubin WR, Jaffe RL. Rapid tranquilization with neuroleptic drugs. Neurologic concerns. Clin Neuropharmacol. 1989 Aug; 12(4):303-11.

View in: PubMed
Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, Ilson J. Tardive dystonia and inappropriate use of neuroleptic drugs. Lancet. 1982 Jun 05; 1(8284):1299.

View in: PubMed
Lidsky TI, Labuszewski T, Levine FM. Are movement disorders the most serious side effects of maintenance therapy with antipsychotic drugs? Biol Psychiatry. 1981 Dec; 16(12):1189-94.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement